Clinical Trials Browser

Completed × Acute Kidney Injury × Plasma cell × Clear all

NCT06549634 2026-02-27

Biomarkers of AKI in Patients Receiving Daratumumab

GenitourinaryPlasma cell

Multiple Myeloma, Acute Kidney Injury

NCT02358980 2025-06-25

KEEPER

GenitourinaryPlasma cell

Multiple Myeloma, Acute Kidney Injury

NCT00120263 2025-03-25

Trial of Plasma Exchange for Acute Renal Failure at the Onset of Myeloma

Phase NA Completed

GenitourinaryPlasma cell

Multiple Myeloma, Neoplasms, Plasma Cell, Acute Kidney Injury

NCT02921828 2022-07-05

A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg

GenitourinaryPlasma cell

Sleepiness, Arrhythmias, Cardiac, Confusion, Consciousness Disorders, Dizziness, Fatigue, Heart Failure, Hypersensitivity, Infections, Jaundice, Liver Diseases, Multiple Myeloma, Peripheral Nervous System Diseases, Thromboembolism, Tumor Lysis Syndrome, Lung Diseases, Interstitial, Acute Kidney Injury, Teratogenesis